Cancer Stem Cell News Volume 3.32 | Aug 20 2014

Cancer Stem Cell News 3.32 August 20, 2014

Cancer Stem Cell News

     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  CSCN on Twitter

Researchers Identify a Mechanism that Stops Progression of Abnormal Cells into Cancer
Researchers report that a tumor suppressor pathway, called the Hippo pathway, is responsible for sensing abnormal chromosome numbers in cells and triggering cell cycle arrest, thus preventing progression into cancer. [Press release from Boston University School of Medicine discussing publication in Cell]
Press Release | Abstract | Graphical Abstract
Learn to Enumerate Mammospheres & Tumorspheres Cultured in MammoCult: Watch Procedure Now

PUBLICATIONS (Ranked by impact factor of the journal)
The Tumor Suppressor Prostate Apoptosis Response-4 (Par-4) Is Regulated by Mutant IDH1 and Kills Glioma Stem Cells
The selective for apoptosis induction in cancer cells domain within Par-4 was highly active against glioma cells, including orthotopic xenografts of patient-derived primary glioma stem cells. [Acta Neuropathol] Abstract

Epigenetic States of Cells of Origin and Tumor Evolution Drive Tumor-Initiating Cell Phenotype and Tumor Heterogeneity
Researchers show how activation of the Sonic Hedgehog pathway in neural stem and progenitor cells creates a foundation for tumor cell evolution to heterogeneous states that are histologically indistinguishable but molecularly distinct. [Cancer Res] Abstract

Phenethyl Isothiocyanate Upregulates Death Receptors 4 and 5 and Inhibits Proliferation in Human Cancer Stem-Like Cells
Researchers examined hitherto unknown effects of the dietary anti-carcinogenic compound phenethyl isothiocyanate on attenuation of proliferation and tumorigenicity and on up regulation of death receptors and apoptosis in human cervical cancer stem cells. [BMC Cancer] Abstract | Full Article

Targeting Melanocyte and Melanoma Stem Cells by 8-Hydroxy-2-Dipropylaminotetralin
Monobenzyl ether of hydroquinone and 8-hydroxy-N,N-dipropyl-2-aminotetralin were added to melanocytes and melanoma cells to compare cytotoxicity. Stem cell content among viable cells was determined by fluorocytometry using markers CD34, Pax3, and CD271. [Arch Biochem Biophys] Abstract

Mechanism of 2′,3′-Dimethoxyflavanone-Induced Apoptosis in Breast Cancer Stem Cells: Role of Ubiquitination of Caspase-8 and LC3
2′,3′-Dimethoxyflavanone (2′,3′-DMF) triggered intrinsic and extrinsic apoptosis by stimulating the cleavage of PARP and the activation of caspase-9, -8, and -3. Interestingly, 2′,3′-DMF induces a dramatic increase in the conversion of LC3, a well-known marker for autophagy. [Arch Biochem Biophys] Abstract

LEF1 Regulates Glioblastoma Cell Proliferation, Migration, Invasion, and Cancer Stem-Like Cell Self-Renewal
Scientists show that knockdown of lymphocyte enhancer factor-1 (LEF1), a major transcription factor of Wnt pathway, inhibits U251 cell migration, invasion, and proliferation. Furthermore, downregulation of LEF1 expression inhibits the self-renewal capacity of U251 glioblastoma multiforme (GBM) stem-like cells and decreases the expression level of the GBM stem-like cell (GSC) markers such as CD133 and nestin. [Tumor Biol] Abstract

Lgr5-Positive Cells Are Cancer Stem Cells in Skin Squamous Cell Carcinoma
Researchers report extremely high Lgr5 levels in the specimen from skin squamous cell carcinoma (SCC) in patients. Using SCC cell line A431, we detected high Lgr5 and CD133 levels in aldehyde dehydrogenase-high or side population from these cancer cells. [Tumor Biol] Abstract

A Stem Cell Medium Containing Neural Stimulating Factor Induces a Pancreatic Cancer Stem-Like Cell-Enriched Population
Cancer stem cells are difficult to study because their population is quite low in tumor specimens. To overcome this problem, researchers established a culture method to induce a pancreatic cancer stem-like cell-enriched population from human pancreatic cancer cell lines. [Int J Oncol] Abstract

Request Your Free Wallchart: Mesenchymal Stem Cells (A Nature Reviews Molecular Cell Biology Collaboration)

Genomic Instability, Driver Genes and Cell Selection: Projections from Cancer to Stem Cells
The identification of driver genes may bring us closer to a mechanistic understanding of the genomic instability of stem cells. Guided by terminologies and methodologies commonly applied in cancer research, such understanding may have important ramifications for both stem cell and cancer biology. [Biochim Biophys Acta] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen
Bristol-Myers Squibb Company and Celgene Corporation announced the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, OPDIVO, and Celgene’s nab® technology-based chemotherapy ABRAXANE®, in a Phase I study. [Bristol-Myers Squibb Company] Press Release

Pfizer Announces Submission of Palbociclib New Drug Application to the FDA
Pfizer Inc. announced it has completed the submission of a new drug application (NDA) to the United States Food and Drug Administration (FDA) for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer who have not received previous systemic treatment for their advanced disease. [Pfizer Inc.] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 21st Stem Cell Network Workshop – Bioengineering and Stem Cells
September 23, 2014
Sydney, Australia

Visit our events page to see a complete list of events in the cancer stem cell community.

NEW Postdoctoral Position – Stem Cell Biology/Cancer Biology (Oregon Health & Science University)

Postdoctoral Research Fellow – Induced Pluripotent Stem Cell Based Therapeutics (Fred Hutchinson Cancer Research Center)

Tenure Track Positions – Cancer Biology (Wake Forest Baptist Medical Center)

PhD Student – Cancer Stem Cells (KU Leuven)

Technical Account Manager (GlobalStem)

Postdoctoral Position – Molecular Properties of Leukemic Stem Cells (BC Cancer Agency)

Postdoctoral Research Associate – Cancer Stem Cell Biology (University of California, San Diego)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Postdoctoral Fellowships – Cancer Research (German Cancer Research Center [DKFZ])

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here

Learn more about Cancer Stem Cell News: Archives | Events | Contact Us